Serialisation is very complex and new legislation for pharmaceutical production is demanding effective solutions. The aim of this new legislation is to decrease the number of counterfeit products in the pharmaceuticals market. Eli Lilly was looking for a precise and reliable serialisation solution that would enable the company to continue guaranteeing the traceability and thereby the safety of its pharmaceutical products.
Stringent quality standards require modern marking solutions to ensure that physicians and patients can rely on the effectiveness and safety of medicines. In their continuous battle against counterfeit products, Lilly Deutschland GmbH places particular emphasis on procedures to ensure this safety and quality.
This special report describes how Lilly Deutschland GmbH is leading the fight against counterfeit medicines as part of a global serialisation plan to protect its pharmaceutical products.